6.
Newsome P, Sasso M, Deeks J, Paredes A, Boursier J, Chan W
. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020; 5(4):362-373.
PMC: 7066580.
DOI: 10.1016/S2468-1253(19)30383-8.
View
7.
Kotronen A, Johansson L, Johansson L, Roos C, Westerbacka J, Hamsten A
. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia. 2009; 52(6):1056-60.
DOI: 10.1007/s00125-009-1285-z.
View
8.
Cuomo P, Capparelli R, Alifano M, Iannelli A, Iannelli D
. Gut Microbiota Host-Gene Interaction. Int J Mol Sci. 2022; 23(22).
PMC: 9698405.
DOI: 10.3390/ijms232213717.
View
9.
Rafaqat S, Gluscevic S, Mercantepe F, Rafaqat S, Klisic A
. Interleukins: Pathogenesis in Non-Alcoholic Fatty Liver Disease. Metabolites. 2024; 14(3).
PMC: 10972081.
DOI: 10.3390/metabo14030153.
View
10.
Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T
. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One. 2012; 7(6):e38322.
PMC: 3375283.
DOI: 10.1371/journal.pone.0038322.
View
11.
Kawai Y, Mimori T, Kojima K, Nariai N, Danjoh I, Saito R
. Japonica array: improved genotype imputation by designing a population-specific SNP array with 1070 Japanese individuals. J Hum Genet. 2015; 60(10):581-7.
PMC: 4635170.
DOI: 10.1038/jhg.2015.68.
View
12.
Aron-Wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom A, Verheij J
. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol. 2020; 17(5):279-297.
DOI: 10.1038/s41575-020-0269-9.
View
13.
Shibata M, Ozato N, Tsuda H, Mori K, Kinoshita K, Katashima M
. Mouse Model of Anti-Obesity Effects of on Diet-Induced Obesity. Curr Issues Mol Biol. 2023; 45(9):7147-7160.
PMC: 10528399.
DOI: 10.3390/cimb45090452.
View
14.
Kawaguchi T, Shima T, Mizuno M, Mitsumoto Y, Umemura A, Kanbara Y
. Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers. PLoS One. 2018; 13(1):e0185490.
PMC: 5791941.
DOI: 10.1371/journal.pone.0185490.
View
15.
Priya S, Burns M, Ward T, Mars R, Adamowicz B, Lock E
. Identification of shared and disease-specific host gene-microbiome associations across human diseases using multi-omic integration. Nat Microbiol. 2022; 7(6):780-795.
PMC: 9159953.
DOI: 10.1038/s41564-022-01121-z.
View
16.
Jasirwan C, Lesmana C, Hasan I, Sulaiman A, Gani R
. The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms. Biosci Microbiota Food Health. 2019; 38(3):81-88.
PMC: 6663510.
DOI: 10.12938/bmfh.18-032.
View
17.
Ozato N, Saito S, Yamaguchi T, Katashima M, Tokuda I, Sawada K
. genus associated with visceral fat accumulation in adults 20-76 years of age. NPJ Biofilms Microbiomes. 2019; 5(1):28.
PMC: 6778088.
DOI: 10.1038/s41522-019-0101-x.
View
18.
Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K
. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012; 47(5):586-95.
DOI: 10.1007/s00535-012-0533-z.
View
19.
Yuan S, Liu H, Yuan D, Xu J, Chen Y, Xu X
. PNPLA3 I148M mediates the regulatory effect of NF-kB on inflammation in PA-treated HepG2 cells. J Cell Mol Med. 2019; 24(2):1541-1552.
PMC: 6991629.
DOI: 10.1111/jcmm.14839.
View
20.
Hosomi K, Saito M, Park J, Murakami H, Shibata N, Ando M
. Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota. Nat Commun. 2022; 13(1):4477.
PMC: 9388534.
DOI: 10.1038/s41467-022-32015-7.
View